Subscribe To
EPZM / Down 54.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Epizyme (EPZM)
EPZM News
By The Motley Fool
June 27, 2022
Why Epizyme Stock Is Soaring Today
A buyout ends Epizyme's 15-year tenure as an independent biopharma. more_horizontal
By Benzinga
June 27, 2022
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
Ipsen SA (OTC: IPSEY) has agreed to acquire Epizyme Inc (NASDAQ: EPZM) at $1.45 per share for approximately $247 million, plus one contingent valu more_horizontal
By Market Watch
June 27, 2022
By Zacks Investment Research
March 31, 2022
Why Is Epizyme (EPZM) Down 29.7% Since Last Earnings Report?
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? more_horizontal
By Zacks Investment Research
March 16, 2022
Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why
Epizyme's (EPZM) lead drug, Tazverik, is approved to treat follicular lymphoma and epithelioid sarcoma in the United States. Stiff competition in the more_horizontal
By Zacks Investment Research
March 2, 2022
Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag
Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. more_horizontal
By Zacks Investment Research
March 2, 2022
Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag
Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. more_horizontal
By Zacks Investment Research
March 2, 2022
Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag
Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. more_horizontal